(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Alexandros Papachristofilou discussing results from the SAKK 01/10 phase II trial testing a single dose of carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B. Seminoma stage IIA/IIB is defined as one or more enlarged lymph nodes in the retroperitoneum or pelvis that are either <= 2 cm (IIA) or 2-5 cm (IIB). Standard treatment options for patients with seminoma clinical stage IIA/B are either extensive “dog-leg” para-aortic/pelvic radiotherapy or 3-4 cycles of cisplatin-based combination chemotherapy with a 3-year progression free survival (PFS) of ~90% (89% with radiotherapy; 92% with chemotherapy), but potential acute and late toxicities. As follows is a table summarizing toxicity post-radiotherapy and post-chemotherapy: